We are live on ! Find out more
CC

Callan Capital Portfolio holdings

AUM $1.35B
1-Year Est. Return 8.35%
This Fund
S&P 500
This Quarter Est. Return
+2.13%
1 Year Est. Return
+8.35%
3 Year Est. Return
+20.11%
5 Year Est. Return
+98.58%
10 Year Est. Return
+95.87%
AUM
$1.22B
AUM Growth
+$77.6M
Cap. Flow
+$59.9M
Cap. Flow %
4.93%
Top 10 Hldgs %
46.33%
Holding
332
New
35
Increased
189
Reduced
69
Closed
18

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$18.4M
2
NMRA icon
Neumora Therapeutics
NMRA
+$4.72M
3
IJH icon
iShares Core S&P Mid-Cap ETF
IJH
+$3.83M
4
AVUV icon
Avantis US Small Cap Value ETF
AVUV
+$3.67M
5
IVW icon
iShares S&P 500 Growth ETF
IVW
+$3.3M

Top Sells

Rank Stock Value
1
VTEB icon
Vanguard Tax-Exempt Bond Index Fund
VTEB
+$1.96M
2
GSIE icon
Goldman Sachs ActiveBeta International Equity ETF
GSIE
+$906K
3
INTF icon
iShares International Equity Factor ETF
INTF
+$852K
4
AVUS icon
Avantis US Equity ETF
AVUS
+$644K
5
DISV icon
Dimensional International Small Cap Value ETF
DISV
+$589K

Sector Composition

Rank Sector Weight
1 Miscellaneous 82.41%
2 Technology 7.75%
3 Healthcare 2.78%
4 Financials 1.79%
5 Communication Services 1.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCS icon
301
Barclays
BCS
$90.2B
$155K 0.01%
14,450
+2,879
+25% +$29.9K
USBC
302
USBC Inc
USBC
$165M
$152K 0.01%
9,250
– –
CRDF icon
303
Cardiff Oncology
CRDF
$73.1M
$144K 0.01%
65,047
+22,300
+52% +$84K
HLN icon
304
Haleon
HLN
$44.5B
$137K 0.01%
16,598
+4,319
+35% +$36.1K
CIO
305
DELISTED
City Office REIT
CIO
$132K 0.01%
26,484
– –
TEF
306
DELISTED
Telefonica
TEF
$124K 0.01%
29,352
+5,792
+25% +$25.6K
NWG icon
307
NatWest
NWG
$73B
$96.8K 0.01%
+12,058
New +$93.6K
IBRX icon
308
ImmunityBio
IBRX
$8.53B
$76.2K 0.01%
12,055
+1,500
+14% +$9.89K
EQ icon
309
Equillium
EQ
$152M
$69.1K 0.01%
99,688
– –
OPI
310
DELISTED
Office Properties Income Trust
OPI
$63.8K 0.01%
31,250
– –
GRAB icon
311
Grab
GRAB
$14.8B
$60.7K 0.01%
17,097
+6,176
+57% +$21.7K
ALLO icon
312
Allogene Therapeutics
ALLO
$698M
$49.1K ﹤0.01%
21,089
– –
DYAI icon
313
Dyadic International
DYAI
$24.6M
$40.2K ﹤0.01%
27,174
– –
VTYX
314
DELISTED
Ventyx Biosciences
VTYX
$37.7K ﹤0.01%
16,310
– –
BMY icon
315
Bristol-Myers Squibb
BMY
$136B
– –
-5,718
Closed -$310K
BTI icon
316
British American Tobacco
BTI
$121B
– –
-8,777
Closed -$268K
CDTX
317
DELISTED
Cidara Therapeutics
CDTX
– –
-4,758
Closed -$87.6K
CI icon
318
Cigna
CI
$73.7B
– –
-712
Closed -$259K
CVS icon
319
CVS Health
CVS
$119B
– –
-2,681
Closed -$214K
ICL icon
320
ICL Group
ICL
$7.23B
– –
-11,192
Closed -$60.2K
ILMN icon
321
Illumina
ILMN
$32.6B
– –
-1,617
Closed -$216K
KR icon
322
Kroger
KR
$35.4B
– –
-3,737
Closed -$213K
RSPT icon
323
Invesco S&P 500 Equal Weight Technology ETF
RSPT
$5.89B
– –
-7,240
Closed -$255K
RYAAY icon
324
Ryanair
RYAAY
$29.1B
– –
-3,440
Closed -$200K
SCZ icon
325
iShares MSCI EAFE Small-Cap ETF
SCZ
$13.3B
– –
-3,524
Closed -$223K
10 11 12
13
14

Similar funds

MBA
Maple-Brown Abbott Barangaroo, Australia $1.47B AUM 27.26% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
AP
Adero Partners Pleasanton, California $1.53B AUM 5.52% 1-Year Est. Return
MW
Marcum Wealth Cleveland, Ohio $1.16B AUM 6.7% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
TW
Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return
PAME
Parvus Asset Management Europe London, United Kingdom $1.67B AUM

Callan Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Callan Capital held 332 positions worth $1.22B, up 6.8% from $1.14B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Callan Capital deployed $59.9M of net new capital in Q2 2024, opening 35 new positions and adding to 189 existing holdings. Its largest new stake was iShares Core S&P Mid-Cap ETF: 65,165 shares worth $3.81M.

By sector, the portfolio is most concentrated in Miscellaneous at 82% of assets, down from 86% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Vanguard Tax-Exempt Bond Index Fund, an estimated $1.96M trimmed.

  • Callan Capital's largest Q2 2024 buy was iShares Core S&P Mid-Cap ETF: 65,165 shares worth $3.81M.
  • Callan Capital added most to NVIDIA in Q2 2024, an estimated $18.4M increase.
  • Callan Capital's biggest Q2 2024 reduction was Vanguard Tax-Exempt Bond Index Fund, cutting an estimated $1.96M.
  • Callan Capital fully exited Takeda Pharmaceutical in Q2 2024, selling an estimated $354K.
  • Callan Capital's ten largest holdings make up 46% of its $1.22B portfolio in Q2 2024.
  • Callan Capital opened 35 new positions and closed 18 in Q2 2024.
  • Callan Capital's portfolio value rose 6.8% quarter-over-quarter to $1.22B.

Based on Callan Capital's 13F filing for Q2 2024, filed 12 Aug 2024.